Literature DB >> 18805957

Lubiprostone activates non-CFTR-dependent respiratory epithelial chloride secretion in cystic fibrosis mice.

Kelvin D MacDonald1, Karen R McKenzie, Mark J Henderson, Charles E Hawkins, Neeraj Vij, Pamela L Zeitlin.   

Abstract

Periciliary fluid balance is maintained by the coordination of sodium and chloride channels in the apical membranes of the airways. In the absence of the cystic fibrosis transmembrane regulator (CFTR), chloride secretion is diminished and sodium reabsorption exaggerated. ClC-2, a pH- and voltage-dependent chloride channel, is present on the apical membranes of airway epithelial cells. We hypothesized that ClC-2 agonists would provide a parallel pathway for chloride secretion. Using nasal potential difference (NPD) measurements, we quantified lubiprostone-mediated Cl(-) transport in sedated cystic fibrosis null (gut-corrected), C57Bl/6, and A/J mice during nasal perfusion of lubiprostone (a putative ClC-2 agonist). Baseline, amiloride-inhibited, chloride-free gluconate-substituted Ringer with amiloride and low-chloride Ringer plus lubiprostone (at increasing concentrations of lubiprostone) were perfused, and the NPD was continuously recorded. A clear dose-response relationship was detected in all murine strains. The magnitude of the NPD response to 20 muM lubiprostone was -5.8 +/- 2.1 mV (CF, n = 12), -8.1 +/- 2.6 mV (C57Bl/6 wild-type, n = 12), and -5.3 +/- 1.2 mV (AJ wild-type, n = 8). A cohort of ClC-2 knockout mice did not respond to 20 muM lubiprostone (n = 6, P = 0.27). In C57Bl/6 mice, inhibition of CFTR with topical application of CFTR inhibitor-172 did not abolish the lubiprostone response, thus confirming the response seen is independent of CFTR regulation. RT-PCR confirmed expression of ClC-2 mRNA in murine lung homogenate. The direct application of lubiprostone in the CF murine nasal airway restores nearly normal levels of chloride secretion in nasal epithelia.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18805957      PMCID: PMC2584880          DOI: 10.1152/ajplung.90221.2008

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  31 in total

1.  Distribution of ClC-2 chloride channel in rat and human epithelial tissues.

Authors:  Joanna Lipecka; Moëz Bali; Annick Thomas; Pascale Fanen; Aleksander Edelman; Janine Fritsch
Journal:  Am J Physiol Cell Physiol       Date:  2002-04       Impact factor: 4.249

Review 2.  ENaC is inhibited by an increase in the intracellular Cl(-) concentration mediated through activation of Cl(-) channels.

Authors:  Karl Kunzelmann
Journal:  Pflugers Arch       Date:  2002-11-20       Impact factor: 3.657

3.  Temporal regulation of CFTR expression during ovine lung development: implications for CF gene therapy.

Authors:  Fiona C Broackes-Carter; Nathalie Mouchel; Deborah Gill; Stephen Hyde; John Bassett; Ann Harris
Journal:  Hum Mol Genet       Date:  2002-01-15       Impact factor: 6.150

4.  Examining basal chloride transport using the nasal potential difference response in a murine model.

Authors:  K G Brady; T J Kelley; M L Drumm
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2001-11       Impact factor: 5.464

Review 5.  Control of epithelial Na+ conductance by the cystic fibrosis transmembrane conductance regulator.

Authors:  K Kunzelmann; R Schreiber; R Nitschke; M Mall
Journal:  Pflugers Arch       Date:  2000-06       Impact factor: 3.657

6.  Loss of hyperpolarization-activated Cl(-) current in salivary acinar cells from Clcn2 knockout mice.

Authors:  Keith Nehrke; Jorge Arreola; Ha-Van Nguyen; Jodi Pilato; Linda Richardson; Gbolahan Okunade; Raymond Baggs; Gary E Shull; James E Melvin
Journal:  J Biol Chem       Date:  2002-04-25       Impact factor: 5.157

7.  Mutations in CLCN2 encoding a voltage-gated chloride channel are associated with idiopathic generalized epilepsies.

Authors:  Karsten Haug; Maike Warnstedt; Alexi K Alekov; Thomas Sander; Alfredo Ramírez; Barbara Poser; Snezana Maljevic; Simon Hebeisen; Christian Kubisch; Johannes Rebstock; Steve Horvath; Kerstin Hallmann; Joern S Dullinger; Birgit Rau; Fritz Haverkamp; Stefan Beyenburg; Herbert Schulz; Dieter Janz; Bernd Giese; Gerhard Müller-Newen; Peter Propping; Christian E Elger; Christoph Fahlke; Holger Lerche; Armin Heils
Journal:  Nat Genet       Date:  2003-03-03       Impact factor: 38.330

8.  The cystic fibrosis transmembrane conductance regulator (CFTR) inhibits ENaC through an increase in the intracellular Cl- concentration.

Authors:  J König; R Schreiber; T Voelcker; M Mall; K Kunzelmann
Journal:  EMBO Rep       Date:  2001-10-17       Impact factor: 8.807

9.  A synthetic prostone activates apical chloride channels in A6 epithelial cells.

Authors:  Hui Fang Bao; Lian Liu; Julie Self; Billie Jeanne Duke; Ryuji Ueno; Douglas C Eaton
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-05-29       Impact factor: 4.052

10.  SPI-0211 activates T84 cell chloride transport and recombinant human ClC-2 chloride currents.

Authors:  John Cuppoletti; Danuta H Malinowska; Kirti P Tewari; Qiu-Ju Li; Ann M Sherry; Myra L Patchen; Ryuji Ueno
Journal:  Am J Physiol Cell Physiol       Date:  2004-06-22       Impact factor: 4.249

View more
  16 in total

1.  Cystic fibrosis growth retardation is not correlated with loss of Cftr in the intestinal epithelium.

Authors:  Craig A Hodges; Brian R Grady; Kirtishri Mishra; Calvin U Cotton; Mitchell L Drumm
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-06-09       Impact factor: 4.052

Review 2.  ClC-2 regulation of intestinal barrier function: Translation of basic science to therapeutic target.

Authors:  Younggeon Jin; Anthony T Blikslager
Journal:  Tissue Barriers       Date:  2015-11-13

3.  Lipid Nanoparticle-Delivered Chemically Modified mRNA Restores Chloride Secretion in Cystic Fibrosis.

Authors:  Ema Robinson; Kelvin D MacDonald; Kai Slaughter; Madison McKinney; Siddharth Patel; Conroy Sun; Gaurav Sahay
Journal:  Mol Ther       Date:  2018-06-15       Impact factor: 11.454

4.  Lubiprostone stimulates secretion from tracheal submucosal glands of sheep, pigs, and humans.

Authors:  N S Joo; J J Wine; A W Cuthbert
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2009-02-20       Impact factor: 5.464

5.  Lubiprostone decreases mouse colonic inner mucus layer thickness and alters intestinal microbiota.

Authors:  Mark W Musch; Yunwei Wang; Erika C Claud; Eugene B Chang
Journal:  Dig Dis Sci       Date:  2013-01-18       Impact factor: 3.199

6.  Lubiprostone: evaluation of the newest medication for the treatment of adult women with constipation-predominant irritable bowel syndrome.

Authors:  Tisha N Lunsford; Lucinda A Harris
Journal:  Int J Womens Health       Date:  2010-10-27

7.  Lubiprostone ameliorates the cystic fibrosis mouse intestinal phenotype.

Authors:  Robert C De Lisle; Racquel Mueller; Eileen Roach
Journal:  BMC Gastroenterol       Date:  2010-09-15       Impact factor: 3.067

8.  Dual activation of CFTR and CLCN2 by lubiprostone in murine nasal epithelia.

Authors:  Eric S Schiffhauer; Neeraj Vij; Olga Kovbasnjuk; Po Wei Kang; Doug Walker; Seakwoo Lee; Pamela L Zeitlin
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-01-11       Impact factor: 5.464

9.  Lubiprostone activates CFTR, but not ClC-2, via the prostaglandin receptor (EP(4)).

Authors:  Yohei Norimatsu; Aurelia R Moran; Kelvin D MacDonald
Journal:  Biochem Biophys Res Commun       Date:  2012-08-29       Impact factor: 3.575

10.  Lubiprostone: clinical applications beyond constipation.

Authors:  Shailendra Kapoor
Journal:  World J Gastroenterol       Date:  2009-03-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.